JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ebert, A. G.
Right arrow Articles by Hess, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ebert, A. G.
Right arrow Articles by Hess, S. M.
Journal of Pharmacology And Experimental Therapeutics, Vol. 148, Issue 3, 412-421, 1965
Copyright © 1965 by American Society for Pharmacology and Experimental Therapeutics


THE DISTRIBUTION AND METABOLISM OF FLUPHENAZINE ENANTHATE

A. G. Ebert 1 and S. M. Hess 1

1 The Squibb Institute for Medical Research, New Brunswick, New Jersey

The distribution of radioactivity, metabolic degradation and mode of action of C14-fluphenazine enanthate (FE) were studied in the rat. Following a single subcutaneous injection of 30 mg of FE per kg as a solution in sesame oil radioactivity was found to have been widely distributed, but the major portion was found in the carcass. The brains contained the least amount of the drug of any of the organs studied. The concentrations decreased from 0.2% of the dose immediately after the injection to 0.04% 21 days later. This amount of drug was sufficient to produce a tranquilizing effect for a 3-week period. A sizable quantity of the dose was found throughout the rat in the form of a nonextractable, nonidentified fraction. In addition to Unchanged FE, 2 metabolites, fluphenazine (F) and fluphenazine sulfoxide (FSO) were identified in the excreta and all the tissues studied except brain. F was the only compound identified in the brain after the injection of either FE or F. The hydrolysis in the brain of FE to F was demonstrated. Radioactivity was excreted in the feces and urine over an extended period.

The experiments support the view that subcutaneously injected FE in oil acted for a prolonged period because the multiple depot sites that had been formed released slowly the active agents, F or FE. Evidence has been presented that the active agent ultimately deposited in the brain was F.

Accepted on January 27, 1965







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics.